BioAge Labs’ Post

We're thrilled to share our latest research on Conditional Average Treatment Effects (CATE) estimation in clinical trials. CATE estimation provides crucial value of understanding treatment effect heterogeneity, which is inherent to designing patient-centered trials. Our extensive simulation study demonstrates the limitation of traditional methods and introduces novel ensemble methods, which present better results across diverse use cases, varying in complexity, sample size, and underlying mechanisms. These robust methods reveal the factors driving heterogeneity in the presence of multiple covariates and complex biological signals, across therapeutic areas and trial types. Understanding the factors driving the heterogeneity enables us to predict treatment effects and probability of success and extract actionable, clinically significant, and business-meaningful insights to maximize the success of the next trial. Oshri Machluf Raviv Pryluk Elad Berkman Tzviel Frostig Gal Shoham Levin Tomer Milo

Very proud to share some of the work we've been busy with, led by Oshri Machluf, Tzviel Frostig, Tomer Milo, Gal Shoham Levin and Raviv Pryluk. Our preprint on Robust CATE Estimation Using Novel Ensemble Methods is now available on arXiv! Causal Machine Learning for CATE estimation is a new and promising approach for identifying heterogeneous treatment effects and promising subgroups in clinical trials. Originally developed in the econometrics domain, this multi-disciplinary approach combines Causal Inference, Machine Learning, and Statistics. In this paper, we compare existing methods across a wide range of scenarios specifically tuned for clinical trials and propose two novel methods with improved robustness. As part of this work, we developed a unique Causal Biological Model of the PD-L1 pathway, trained on real clinical data, and used it to create more realistic data for our benchmarking. This is yet another example of how integrating biology and machine learning can drive innovation. Excited to see the impact this will have on the future of clinical trials!

We are excited to participate in the first BioLabs European Investor Day in Paris! 🌎 🇫🇷 Europe’s top biotech startups and the most active European and international life science investors will come together on March 19th to advance medicine. We are honored to present our contributions to the earlier and precise diagnosis of Acute Kidney Injury (AKI). The Sciomics scioAKI project has identified promising early biomarker combinations for perioperative AKI with a very strong diagnostic performance. Based on these results, a new spin-off will be dedicated to the development of a reliable and easy-to-use test for the early diagnosis of AKI in a clinical setting. Saving kidneys, saving lives! 🏥 #BioLabsEuropeanInvestorDay #precisionmedicine #acutekidneyinjury #proteomics

Exciting Research News! 🚀 I am thrilled to announce that our manuscript, "Learning Good Therapeutic Targets in ALS and Neurodegeneration Using Observational Studies", is now live on MedRxiv! It has been an incredible journey contributing to neurodegenerative disease research, particularly for amyotrophic lateral sclerosis (ALS). In this study, we developed an innovative ALS-specific pathway model by leveraging patient data, public sources, and large-scale consortia. With this model, we simulated drug effects on ALS progression and evaluated their impact on overall survival through retrospective electronic health records (EHR) studies. This represents an advancement toward accelerating target discovery, with the potential to transform ALS treatment strategies. 🎉 A sincere thank you to Sanofi and their exceptional team, whose collaboration was pivotal in the success of this project. Their expertise in computational biology and real-world data (RWD) platforms added invaluable insights, underscoring the strength of academia-industry partnerships in advancing healthcare innovation. We are excited about the potential of this work to address critical unmet therapeutic needs in neurodegenerative diseases, and we look forward to the next steps! 🔗 Check out the preprint here: [https://lnkd.in/gRfUcD5r] #ALSResearch #Neurodegeneration #Bioengineering #RWD #TargetDiscovery #Pharma #UCLA #Sanofi #Collaboration #MedRxiv

We've just published some exciting research in #MedicinalChemistry! 🚀 Together with the team at Domain Therapeutics we explored the mysteries of orphan G-protein coupled receptors (GPCRs), specifically GPR88 (see comments for the links). 👉 Some personal notes before we dive into science: A big shout-out to everyone who contributed! This project was far from being straightforward. Not only were the molecules hard to synthesize, but also our target is a tough nut to crack (see below). I am grateful for the team spirit that prevailed throughout all the challenges we faced. Also, a huge thanks to Florian Montel and Mickaël FER for the countless hours working on the paper – MERCI! 🧐 Now some scientific context: GPCRs are the largest family of human proteins and they play a key role in many physiological and pathological functions. One of these, GPR88, is often linked to various neurological disorders. We believe that by understanding more about this target, we can create value for patients. 🤜 Our work in a nutshell: The development of new GPR88 agonists has been tricky due to poor pharmacokinetic properties. Our recent study has brought us closer to overcome these hurdles with BI-9508, a brain-penetrant GPR88-receptor-agonist tool compound. Our findings not only pave the way for more CNS research, but also highlight the necessary trade-offs to effectively target GPR88’s allosteric pocket. 👌 Here's the best part: we're making this new tool compound available to the scientific community for FREE via Boehringer Ingelheim's open innovation portal: opnMe. In the comments below: Check out our paper and the opnMe website where you can order BI-9508 for free. #lifeforward #openscience

How do Central Labs ensure reliability across global clinical trials? In our latest Q&A, Pagona Manika, shares insights into the critical role Central Labs play in ensuring consistency, managing biological samples, and advancing specialized testing. Here’s what Pagona covers: 🔹 How Central Labs ensure consistent, reliable data across multiple locations 🔹 Challenges Central Labs help overcome in sample management and storage 🔹 The importance of Central Labs in providing advanced, specialized testing 🔹 How Central Labs adapt to the complexity of biomarker analysis in personalized medicine and oncology trials Have more questions about clinical research? Drop them in the comments below and we’ll answer them in upcoming posts! 💬 #CentralLabs #ClinicalResearch #BiomarkerAnalysis #PersonalizedMedicine #YourQuestionsExpertAnswers #ClinicalTrials #HealthTech

We hope to see you at the 2nd Annual MarketsandMarkets ImmunoBio Series. Discover how our AI-powered spatial biology tools for exploring the tumor microenvironment deliver quantitative, high confidence insights in just a fraction of the time of conventional methods. On October 15 at 10:00 am CEST, Angela Vasaturo, Director of Scientific Affairs at Ultivue, will present: “Ultrasensitive ISP assays for high quality spatial insights.” ➡️See how Ultivue’s ultrasensitive InSituPlex® assays capture an unprecedented view into the vast complexity of cellular interactions within the tumor microenvironment and enable researchers to localize biomarkers directly within tissue. ➡️Learn how InSituPlex technology enhances understanding of spatial tissue biology at scale, reducing biomarker-based analytic cycle times by more than 70% and accelerating the drug development process. ➡️Angela will also share new data demonstrating how the technology’s proprietary signal amplification enables biomarker detection with significantly higher sensitivity, compared to alternate approaches. We hope to see you there! #Spatialbiology #cancerresearch

🤝🏻 We have successfully completed our collaboration with the Welch research group at The Babraham Institute to evaluate lead compounds predicted to bind a pro-inflammatory protein identified in our pilot studies. The project was funded by the UKRI-BBSRC Campus Innovation Award (CIA), via the Babraham Research Campus Collaboration Fund in October 2023. The collaboration demonstrates that new disease-specific targets identified in our trial have the potential to be modifiable by small molecule drugs—opening new opportunities for a precision medicine approach to heart disease. We are now evaluating the target in our ongoing BIOPATTERN trial and, if validated, further development will be pursued. Read more ➡ https://rb.gy/6b1o61 #CoronaryArteryDisease #Collaboration #ClinicalTrial #PrecisionMedicine #HeartDisease

👩🔬 Barbara Lösch PhD, our Head of Technology and Innovation, joined the DACH Symposium 2024: Empowering Research & Drug Development in Biomedicine, taking place in Basel on September 24, 2024. She provided an overview of our Universal tagging and tracking system UniTope & TraCR technology. This technology is a component of our End-to-End Platform, featuring two specialized tools that uniquely tag TCRs and accurately track their location. This enables precise monitoring of TCR-guided cell therapies, including their proliferation, persistence, and localization, both in vitro and in vivo. As a result, it provides essential insights into the efficacy and underlying mechanisms of cell therapies. 👉Recent data on UniTope & TraCR technology were presented at the ESMO Congress 2024 in Barcelona. Find here the poster: https://lnkd.in/d5xb6Nx6 👉More information about the conference: https://lnkd.in/g8nJE3ix

C-Path is thrilled to welcome Wave Life Sciences as the newest member of its Duchenne Regulatory Science Consortium. Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Joining forces with Wave Life Sciences strengthens our collective commitment to advancing regulatory science in Duchenne muscular dystrophy research. Together, we're paving the way for innovative treatments and improved outcomes for patients. Welcome aboard, Wave Life Sciences! 👏 Ramona Belfiore-Oshan #CPath #DMD #globalhealth #drugdevelopment #datasharing #DuchenneResearch #Collaboration #Innovation #WaveLifeSciences